Two-Dimensional (Crossed) Immunoelectrophoresis

2003 ◽  
pp. 299-310
Author(s):  
John M. Walker
1985 ◽  
Vol 54 (03) ◽  
pp. 626-629 ◽  
Author(s):  
M Meyer ◽  
F H Herrmann

SummaryThe platelet proteins of 9 thrombasthenic patients from 7 families were analysed by high resolution two-dimensional gel electrophoresis (HR-2DE) and crossed immunoelectrophoresis (CIE). In 7 patients both glycoproteins (GPs) IIb and Ilia were absent or reduced to roughly the same extent. In two related patients only a trace of GP Ilb-IIIa complex was detected in CIE, but HR-2DE revealed a glycopeptide in the position of GP Ilia in an amount comparable to type II thrombasthenia. This GP Ilia-like component was neither recognized normally by anti-GP Ilb-IIIa antibodies nor labeled by surface iodination. In unreduced-reduced two-dimensional gel electrophoresis two components were observed in the region of GP Ilia. The assumption of a structural variant of GP Ilia in the two related patients is discussed.


1977 ◽  
Vol 23 (2) ◽  
pp. 186-194 ◽  
Author(s):  
J E Rerabek

Abstract I report the pattern of low-density lipoproteins (LDL) and very-low-density lipoproteins (VLDL) as revealed by two-dimensional (crossed) immunoelectrophoresis in hyperlipoproteinemia types, II, III, and IV, preliminarily diagnosed by means of a complex lipoprotein profile examination. The higher affinity of Oil Red stain for VLDL- than for LDL-immunoprecipitation zones is peculiar to this lipoprotein class, and crossed immunoelectrophoretograms may thus be helpful for laboratory diagnosis of types IIb and IV in problematic cases. The position and the medium affinity for Oil Red of "broad beta" zones appearing in immunoelectrophoretograms of type III hyperlipoproteinemia are suggested as useful criteria for the diagnosis of this condition. From the structural and staining characteristics of VLDL-immunoprecipitation zones, alteration of both composition and antigenic properties of VLDL in hyperlipoproteinemias IIb-IV is deduced. I present in detail the procedure for crossed immunoelectrophoresis as well as that for the lipoprotein profile examination used in this study.


Blood ◽  
1990 ◽  
Vol 76 (9) ◽  
pp. 1698-1703 ◽  
Author(s):  
N Yamamoto ◽  
H Ikeda ◽  
NN Tandon ◽  
J Herman ◽  
Y Tomiyama ◽  
...  

Abstract It has recently been shown that the Naka antigen, which is absent in 3% to 11% of Japanese blood donors, is expressed on platelet glycoprotein IV (GPIV; CD36) (Tomiyama et al, BLOOD, 75:684, 1990). In the present studies, flow cytometry was used to distinguish differences in the reactivity of Naka+ and Naka- platelets with both OKM5, a monoclonal antibody that recognizes an epitope on GPIV, and with polyclonal anti- GPIV antibody. OKM5 was also used to screen 871 platelet concentrates prepared from healthy US blood donors. Three of these showed markedly deficient binding of 125I-OKM5 or an incidence of 0.34%. Two of these donors were re-accessed and showed less than 1% binding of 125I-OKM5 as compared with 10,300 +/- 1,500 binding sites per platelet in controls (n = 4). Platelets from these two US donors were radiolabeled (125I, 3H) and compared with control platelets and with platelets from Japanese Naka+ and Naka- donors by crossed immunoelectrophoresis, protein blots, immunoprecipitation, and two-dimensional gel electrophoresis. GPIV could not be detected by any of these techniques in the Naka- platelets nor in the donors whose platelets showed deficient binding of OKM5. These results suggest that GPIV functions as an isoantigen rather than an alloantigen in immunizing Naka- platelet recipients. This is the first report of the absence of a major platelet membrane GP in healthy blood donors.


1983 ◽  
Vol 4 (2) ◽  
pp. 165-167
Author(s):  
Calvin A. Saravis ◽  
Richard B. Cook ◽  
Christian E. Sampson ◽  
William J. Polvino

Blood ◽  
1990 ◽  
Vol 76 (9) ◽  
pp. 1698-1703 ◽  
Author(s):  
N Yamamoto ◽  
H Ikeda ◽  
NN Tandon ◽  
J Herman ◽  
Y Tomiyama ◽  
...  

It has recently been shown that the Naka antigen, which is absent in 3% to 11% of Japanese blood donors, is expressed on platelet glycoprotein IV (GPIV; CD36) (Tomiyama et al, BLOOD, 75:684, 1990). In the present studies, flow cytometry was used to distinguish differences in the reactivity of Naka+ and Naka- platelets with both OKM5, a monoclonal antibody that recognizes an epitope on GPIV, and with polyclonal anti- GPIV antibody. OKM5 was also used to screen 871 platelet concentrates prepared from healthy US blood donors. Three of these showed markedly deficient binding of 125I-OKM5 or an incidence of 0.34%. Two of these donors were re-accessed and showed less than 1% binding of 125I-OKM5 as compared with 10,300 +/- 1,500 binding sites per platelet in controls (n = 4). Platelets from these two US donors were radiolabeled (125I, 3H) and compared with control platelets and with platelets from Japanese Naka+ and Naka- donors by crossed immunoelectrophoresis, protein blots, immunoprecipitation, and two-dimensional gel electrophoresis. GPIV could not be detected by any of these techniques in the Naka- platelets nor in the donors whose platelets showed deficient binding of OKM5. These results suggest that GPIV functions as an isoantigen rather than an alloantigen in immunizing Naka- platelet recipients. This is the first report of the absence of a major platelet membrane GP in healthy blood donors.


Sign in / Sign up

Export Citation Format

Share Document